Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder
Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in…
Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in…
-Top-line results planned to be released in third quarter 2023- -Trial results are intended to…
-Top-line results planned to be released in third quarter 2023- -Trial results are intended to…
MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy…
ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy…
DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN)…
DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN)…
Conference call scheduled for 8:00 a.m. Eastern Time WALTHAM, Mass., July 26, 2023 (GLOBE NEWSWIRE)…
Conference call scheduled for 8:00 a.m. Eastern Time WALTHAM, Mass., July 26, 2023 (GLOBE NEWSWIRE)…
SOUTH ORANGE, NJ, July 26, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Nephros, Inc. (Nasdaq:…
SOUTH ORANGE, NJ, July 26, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Nephros, Inc. (Nasdaq:…
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical…
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical…
First shipment of D*gg lbs (pronounced “dog pounds”) from the Company’s EU GMP facility in…
First shipment of D*gg lbs (pronounced “dog pounds”) from the Company’s EU GMP facility in…
– Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint…
– Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint…
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the…